Fundraising Fox

Valitor

Berkeley, US · Founded 2018 · Delaware corporation · 8 known investors

Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.

BiotechMedical Devices

Founders & leadership

WJWesley Jackson
Wesley JacksoninPresident, Chief Scientific Officer & Member of the Board
GD
Gregory D. KunstChief Executive Officer
CH
Carole H BellisNamed on SEC filing
KE
Kevin E HealyNamed on SEC filing
JM
Jackson M WesleyNamed on SEC filing

Board

DLDrew Lanza
Drew LanzainBoard directorPartner at Berkeley Catalyst
WMWalter Moos
Walter MoosBoard directorManaging Director at Pandect Bioventures

Investors · 8

Angel Physicians Fund
Berkeley CatalystBerkeley
ExSight VenturesNew York
First Spark Ventures, LlcMenlo Park
Pandect BioventuresWoodside
ExSightreportedNew York

Also in the syndicate · 2

Berkeley Catalyst FundMorningsidelead

Funding

SEC filings, press & company announcements

$38.2M disclosed across 3 rounds · 2018–2022

▶$8.4MraisedJan 2022 · 8 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Walter MoosDirector
  • Anthony AiudiDirector
  • Kevin E. HealyDirector
  • Gail MaderisDirector
  • Manish KothariDirector
  • Wesley M. JacksonExecutive Officer, Director
Offering amount
$32.7M
Amount sold
$8.4M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedSep 2018 · 6 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Carole H BellisExecutive Officer
  • Drew LanzaDirector
  • Kevin E HealyDirector
  • Walter MoosDirector
  • Jackson M WesleyExecutive Officer, Director
Offering amount
$2.8M
Amount sold
$1.7M
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Volitionrx3 shared keywordsVolition develops Nu.Q epigenetics-based blood tests that detect nucleosome changes associated with cancer, sepsis, and other diseases in both humans and animals. Its products include diagnostic assays for NETosis detection, research-use assays, and a canine cancer blood test.
Valo3 shared keywordsValo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields. It positions itself as a company focused on reshaping how new drugs are discovered.

Companies competing with Valitor for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 9 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$299.3K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$298.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$224.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2017$224.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$318.1K
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$284.6K
National Institutes of Health (NIH)National Institutes of HealthPhase II2014$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2013$310.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$311.2K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Valitor Closes $28M Series B Financing - FinSMEsfinsmes.com · Oct 2022ExSight participates in Valitor’s $28 million Series B to fund Multivalent Polymer (MVP) technology platform’s development.<br/> — ExSight Venturesexsightventures.com · Oct 2022Valitor Raises $28M Series B to Develop Therapy for Age-Related Macular Degeneration - Bakar Labsbakarlabs.berkeley.edu · Oct 2022Valitor Announces the Closing of its Series B Financing and Names Steven Lo as Chief Executive Officerglobenewswire.com · Oct 2022

Frequently asked questions

What does Valitor do?
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.
Who are Valitor's investors?
Valitor's investors include Angel Physicians Fund, Berkeley Catalyst, ExSight Ventures, First Spark Ventures, Llc, Pandect Bioventures, ExSight.
How much funding has Valitor raised?
Valitor has disclosed $38.2M raised across 3 rounds.
Where is Valitor headquartered?
Valitor is headquartered in Berkeley, US.